Showing results (571-580 of 688) with videos related to

Sort By:
Pageof 69
Methods in Molecular Biology (Clifton, N.J.)|May 19, 2026
Complex Structural Examination of Protein-Lipid Interactions with Neutron Scattering TechniquesNajet Mahmoudi, Hannah Johnston, Sophie E Ayscough, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|July 10, 2023
Predicting Slow Walking Speed From a Pooled Cohort Analysis: Sarcopenia Definitions, Agreement, and Prevalence in Australia and New ZealandJesse Zanker, David Scott, Cassandra Szoeke, et al.
Plos One|August 23, 2012
Glutamine repeat variants in human RUNX2 associated with decreased femoral neck BMD, broadband ultrasound attenuation and target gene transactivationNigel A Morrison, Alexandre A Stephens, Motomi Osato, et al.
The Journal of Rheumatology|November 3, 2005
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Gerald Krueger, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Therapeutic Advances in Musculoskeletal Disease|November 13, 2024
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studiesLars Erik Kristensen, William Tillett, Peter Nash, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.
Pediatric Blood & Cancer|July 23, 2026
Short Course Cefixime to Prevent Irinotecan-Associated Diarrhea in Children With Solid Tumors: A Retrospective AnalysisMegan R Wright, Shane J Cross, Ted Morton, et al.
The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
Pageof 69